Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25037740 | 0.86 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL23628245 | 0.79 | HSD11B1 (0.40) | AKR1B1HSD11B1PDK2HTTFABP4 | |
| SCHEMBL24206291 | 0.78 | WDR5 (0.35) | HSD11B1HTTKDM4EALDH1A1HPGD | |
| SCHEMBL24316341 | 0.74 | SLC6A3 (0.41) | HSD11B1KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL24316340 | 0.74 | CYP1A2 (0.37) | HSD11B1PDK2HTTKDM4EALDH1A1 | |
| SCHEMBL25878965 | 0.72 | PDK2 (0.42) | HSD11B1PDK2MEN1KMT2AFABP4 | |
| SCHEMBL25878966 | 0.72 | PDK2 (0.42) | HSD11B1PDK2HTTMEN1ALDH1A1 | |
| SCHEMBL24316402 | 0.71 | PDK2 (0.31) | HSD11B1PDK2 | |
| SCHEMBL23177230 | 0.70 | SLC6A2 (0.44) | HSD11B1PDK2MEN1ALDH1A1HPGD | |
| SCHEMBL25501503 | 0.70 | PDK2 (0.39) | HSD11B1PDK2ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2022068292-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | 陕西莱特光电材料股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11800792-B2 | Organic compound with spirocyclic adamantane, and electronic element and electronic device using same | OR51E2, SQLE, ODC1 | AKR1B1 1268/4885HSD11B1 588/4885PDK2 327/4885 |
| US-20230052660-A1 | NITROGEN-CONTAINING COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | NOD1, NFE2L2, NOTCH1 | AKR1B1 3619/4885HSD11B1 2932/4885PDK2 3491/4885 |
| US-20230200215-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | LEF1, OCIAD1, OR10J3 | AKR1B1 3126/4885HSD11B1 1933/4885PDK2 705/4885 |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | NOD1, NFE2L2, NOTCH1 | AKR1B1 3619/4885HSD11B1 2932/4885PDK2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.